Hikma Pharmaceuticals Plc Notice of Results (3273V)
July 23 2018 - 4:00AM
UK Regulatory
TIDMHIK
RNS Number : 3273V
Hikma Pharmaceuticals Plc
23 July 2018
London, 23 July 2018 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) (LEI: 549300BNS685UXH4JI75), the multinational generic
pharmaceutical company, will announce its interim financial results
for the six months ended 30 June 2018 on Wednesday 15 August
2018.
A presentation and webcast for analysts will be held at 9.30am
BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate
Street, London, EC1A 4HD, with registration and coffee from
9.15am.
To join via conference call please dial:
UK Toll Free Number: 020 3936 2999
US Toll Free Number: 1 855 9796 654
Standard International Access: +44 20 3936 2999
Password: 911652
The results presentation and a webcast recording of the event
will be available on the Company's website at www.hikma.com or
http://webcast.openbriefing.com/hikma_interim_results_2018/.
Playback facility:
A playback of the conference call will be available after the
presentation.
United Kingdom - 020 3936 3001
United States - 1 845 709 8569
All other locations - + 44 20 3936 3001
Replay code: 338668
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
VP Corporate Strategy and Director +44 (0)20 7399 2760/ +44 7776
of Investor Relations 477050
Virginia Spring +44 (0)20 3892 4389/ +44 7973
Investor Relations Manager 679502
FTI Consulting
Ben Atwell/Brett Pollard +44 (0)20 3727 1000
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
40 years, we've been creating high-quality medicines and making
them accessible to the people who need them. We're a global company
with a local presence across the United States (US), the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,500 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner in
the MENA region, and through our venture capital arm, are helping
bring innovative health technologies to people around the world.
For more information, please visit www.hikma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORGMGZNMGVGRZM
(END) Dow Jones Newswires
July 23, 2018 04:00 ET (08:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024